Get ahead in your career - track and evidence all your medical learning

Prostate cancer: triptorelin (Decapeptyl SR) | Key-points-from-the-evidence | Advice | NICE

In 2013, the licensed indications for the luteinising hormone-releasing hormone (LHRH) agonist, triptorelin (Decapeptyl SR), were extended to include 2 new indications for prostate cancer: neoadjuvant treatment before radiotherapy in high-risk localised or locally advanced disease, and adjuvant t...
Shared on Wednesday 28th October 2015